Cargando…
Subcutaneous amyloidoma models for screening potential anti-fibrillating agents in vivo
Here, we describe a robust protocol using mouse models to screen potential insulin-stabilizers and insulin moieties. We have generated a mouse model of amyloidoma, found in diabetic patients undergoing insulin therapy. This model can be used to screen potential insulin stabilizers and insulin moieti...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683767/ https://www.ncbi.nlm.nih.gov/pubmed/34977673 http://dx.doi.org/10.1016/j.xpro.2021.101027 |
_version_ | 1784617486987034624 |
---|---|
author | Das, Debajyoti Paul, Avishek Maity, Sujay Krishna Chatterjee, Subhrangsu Chakrabarti, Partha |
author_facet | Das, Debajyoti Paul, Avishek Maity, Sujay Krishna Chatterjee, Subhrangsu Chakrabarti, Partha |
author_sort | Das, Debajyoti |
collection | PubMed |
description | Here, we describe a robust protocol using mouse models to screen potential insulin-stabilizers and insulin moieties. We have generated a mouse model of amyloidoma, found in diabetic patients undergoing insulin therapy. This model can be used to screen potential insulin stabilizers and insulin moieties to prevent amyloidoma formation. This protocol can further be used for the preclinical validation of therapeutically relevant insulin stabilizers and formulations. The protocol highlights all the critical steps for generating amyloidoma in a preclinical model. For complete details on the use and execution of this profile, please refer to Mukherjee et al. (2021). |
format | Online Article Text |
id | pubmed-8683767 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-86837672021-12-30 Subcutaneous amyloidoma models for screening potential anti-fibrillating agents in vivo Das, Debajyoti Paul, Avishek Maity, Sujay Krishna Chatterjee, Subhrangsu Chakrabarti, Partha STAR Protoc Protocol Here, we describe a robust protocol using mouse models to screen potential insulin-stabilizers and insulin moieties. We have generated a mouse model of amyloidoma, found in diabetic patients undergoing insulin therapy. This model can be used to screen potential insulin stabilizers and insulin moieties to prevent amyloidoma formation. This protocol can further be used for the preclinical validation of therapeutically relevant insulin stabilizers and formulations. The protocol highlights all the critical steps for generating amyloidoma in a preclinical model. For complete details on the use and execution of this profile, please refer to Mukherjee et al. (2021). Elsevier 2021-12-14 /pmc/articles/PMC8683767/ /pubmed/34977673 http://dx.doi.org/10.1016/j.xpro.2021.101027 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Protocol Das, Debajyoti Paul, Avishek Maity, Sujay Krishna Chatterjee, Subhrangsu Chakrabarti, Partha Subcutaneous amyloidoma models for screening potential anti-fibrillating agents in vivo |
title | Subcutaneous amyloidoma models for screening potential anti-fibrillating agents in vivo |
title_full | Subcutaneous amyloidoma models for screening potential anti-fibrillating agents in vivo |
title_fullStr | Subcutaneous amyloidoma models for screening potential anti-fibrillating agents in vivo |
title_full_unstemmed | Subcutaneous amyloidoma models for screening potential anti-fibrillating agents in vivo |
title_short | Subcutaneous amyloidoma models for screening potential anti-fibrillating agents in vivo |
title_sort | subcutaneous amyloidoma models for screening potential anti-fibrillating agents in vivo |
topic | Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683767/ https://www.ncbi.nlm.nih.gov/pubmed/34977673 http://dx.doi.org/10.1016/j.xpro.2021.101027 |
work_keys_str_mv | AT dasdebajyoti subcutaneousamyloidomamodelsforscreeningpotentialantifibrillatingagentsinvivo AT paulavishek subcutaneousamyloidomamodelsforscreeningpotentialantifibrillatingagentsinvivo AT maitysujaykrishna subcutaneousamyloidomamodelsforscreeningpotentialantifibrillatingagentsinvivo AT chatterjeesubhrangsu subcutaneousamyloidomamodelsforscreeningpotentialantifibrillatingagentsinvivo AT chakrabartipartha subcutaneousamyloidomamodelsforscreeningpotentialantifibrillatingagentsinvivo |